| External factors: | TPL |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | Cell cycle analysis |
| Description: | TPL accelerated cellular senescence in a dose-dependent manner. Compared with control group, HepG2 cells treated with TPL had an increased percentage of cells at G0/G1 phase and decreased percentage of cells at G2/M phase. |
| Regulatory pathway: | p53-p21//Akt//hTERT |
| R-EF-Pathway: | Upregulation//Activation//Downregulation |
| Official symbol(s): | TP53-CDKN1A//AKT1//hTERT |
| Pathway experiment: | Western blot//RT-PCR |
| Pathway description: | The p53/p21 signaling pathway is the key regulatory pathway of the cell cycle. Treatment of HepG2 cells with TPL significantly increased the expression levels of p53 and p21 and decreased the cyclin D1 expression, suggesting that TPL arrests cells at G0/G1 phase by regulating the p53/p21 pathway.Treatment of HepG2 cells with TPL significantly increased phosphorylated AKT level while phosphorylated AKT level reduced after treatment with TPL and MK2206 (AKT inhibitor), indicating that TPL could enhance phosphorylated AKT level and activated the AKT pathway.TPL inhibited telomerase activity and hTERT expression in a time-dependent manner. |
Annotation: